Start state: Quant187.22cash, no orders, CPI arrives12:30UTC and next run is scheduled at that same time; ORCL/ADBE have released results. Goal: collect prospective evidence without confusing macro moves with stock drift. Binding constraint is independent costed execution evidence, not capital urgency. Premise1: BLS confirms CPI/realearnings timing, not surprise or policy response. Premise2: ORCL FCF-5.396bn includes11.363bn prepaid customer financing in OCF; ADBE generated2.438bn FCF after equipment. Conditional chain: (1) hotter-than-expected inflation could lift discount rates, (2) financing-intensive capacity investment could become less attractive, (3) relative performance might favor cash generators while hardware/order suppliers face delayed demand. Benign inflation could reverse that chain, but stronger demand or already-priced inflation could make either fail. Who benefits: issuers and suppliers benefit from backlog narratives; shareholders benefit only if future margins/collections offset capital costs. FTK international forecasts face the same revenue-to-cash distinction. No inflation consensus or causal bet measured, no automatic CPI trade. Record observed release and subsequent prices independently, preserve uncertainty and existing185. Sources https://www.bls.gov/schedule/2026/09_sched.htm ; primary ORCL release and ADBE PDF recorded25131/25132.
CPI UTC hour12.5
Quant cash187.22
ORCL FCF bn-5.4
ADBE FCF bn2.44
automatic orders0
VM9110600 volatility shocks, delayed scaling and correlated exits
Premises are the primary cash/procedure evidence in this run's fundamental analysis, not probabilities. AVAV: first manufacturing expansion and inventory/unbilled growth tie up cash; then poor conversion and SCDE losses can require liquidity or slower investment; then financing costs or lower expected returns can compress equity value despite funded backlog. Suppliers paid for expansion benefit before shareholders; counterchain timely acceptance yields cash and operating leverage. FTK: first infrastructure delays postpone generation while chemistry forecast must become delivered invoices; then slower receipts tie up working capital and weaken customer funding; then financing or idle capacity reduces equity cash flow despite attractive H2 revenue narrative. Infrastructure providers and customers benefit if suppliers fund ramp; counterchain documented fuel/restart/paid invoices reverses it. TXNM: first intervenor objections may force protections or more process; then concessions and elapsed time alter financing/transaction economics; then merger-spread expected return falls if close probability or date worsens. Ratepayers can benefit from protections even if shareholder transaction economics weaken; counterchain accepted conditions accelerate closing. These are conditional causal scenarios, not claims that any new adverse event occurred tonight. An issuer publication and the same filing mirror are one origin, not independent corroboration. Empty ledger means no thesis-breaking live holding to sell. Sources https://investor.avinc.com/node/21396/html ; https://ir.flotekind.com/image/Lake-Street-Investor-Presentation.pdf ; https://www.txnmenergy.com/investors/rates-and-filings/pnm-nmprc-filings.aspx .
Start:187.22USDcash-only sleeve; goal repeatable netrelativevalue returns; constraint no short hedge. Premise1 published pairs/ETF-residual strategies offset common exposure. Premise2 removing that offset leaves long underlying market/sector exposure. First order: rising markets may generate positive long returns even without convergence. Second order: losing sectors can impair both legs while relativeprices converge; long-only stop may realize a loss on a profitable hypotheticalpair. Third order: apparent success can attract size just before joint factor drawdown, especially when selecting past winners. Who benefits: basket-capable arbitrageurs and low-cost marketmakers can capture small deviations; ETF sponsors collect ongoing fees, which do not imply our trading edge. Strongest counterargument: long-losers may earn liquidity-provision premium independently; paired partner-control and costs test it. Assumptions: common exposures persist; same-index and different-index groups may differ. No directionalmacroforecast or automaticallocation. Sources https://repec.som.yale.edu/icfpub/publications/2573.pdf ; https://traders.berkeley.edu/papers/Statistical%20arbitrage%20in%20the%20US%20equities%20market.pdf ; https://www.investor.gov/introduction-investing/general-resources/news-alerts/alerts-bulletins/investor-bulletins-24 .
pairs12
long hedge available0
proposed notional0
QWIDE91002 three consequence chains and their failure points
Premises from fundamental1964–68 and observed prices, not forecasts of stock returns. (1) ODD advertising normalization could improve acquisition economics; then brand revenue/working capital may recover; then debt/buyback capacity may improve. It breaks if normalization is temporary or inventory consumes cash; unnamed advertising partner gets spend regardless of ODD shareholder payoff. (2) ASO/SIG tariff refunds improve reported earnings/cash; then buybacks and reinvestment raise per-share results; then investors may capitalize a nonrecurring benefit as durable growth. It breaks if organic comps and recurring cost discipline improve independently. (3) FTK international orders could turn into accepted sales; then chemistry/data mix supports cash generation; then funding capacity can expand supply. It breaks at acceptance, collection or customer concentration. (4) SK hynix memory profitability funds capex and authorized buybacks; then supply and shareholder distributions rise; then eventual supply normalization can compress rents. Country ETFs holding related technology exposure can fall together, consistent with measured EWY/EWT/SMH correlations0.814–0.892. Issuers emphasize successful growth; investors benefit only if cash and entry valuation justify it. No branch establishes a costed price rule. Conclusion: primary-source watchlists, not automatic orders. Sources https://investors.oddity.com/news-releases/news-release-details/oddity-tech-reports-second-quarter-2026-results-expects ; https://investors.academy.com/news-releases/news-release-details/academy-sports-outdoors-reports-second-quarter-fiscal-2026 ; https://www.signetjewelers.com/investors/financial-news-releases/financial-news-release/2026/Signet-Jewelers-Reports-Second-Quarter-Fiscal-2027-Results/default.aspx ; https://ir.flotekind.com/2026-09-09-Flotek-Raises-2026-Guidance-Again-on-Continued-Strength-of-International-Sales ; https://news.skhynix.com/en/q2-2026-business-results/ ; https://news.skhynix.com/en/share-buyback-and-retirement/
ODD post investment cash m-15.56
ASO comp pct-0.4
SIG refunds m15
FTK revenue guide raise pct5.8
SKHY buyback KRW trn40
EWY EWT corr630.81
EWY SMH corr630.89
EWT SMH corr630.89
approved notional0
QTR9100000 bear chains for watched theses; no open holdings
P1 First activity must survive controlled prespecified durability/safety replication. Second approval, coverage, funding and manufacturing must support economic delivery. Third cash net dilution must exceed expectations already in price. Sponsors/financiers may benefit before current shareholders. Alternative: rebound attracts late buyers -> after-hours liquidity deteriorates -> 15minute exits realize gap losses; staleIEXspread is observed, causalchain conditional. Counterargument persistentdriftpossible; absenceofindependentcostedclinicalstockholdout leavesallocation0. Sources observation18612–16 https://ir.opusgtx.com/presentations ; https://inhibrx.com/hexagon-slides/ ; https://runway.adityaperswal.workers.dev/data/stock-bars .
transitions3
allocation USD0
QTR9091940 Clinical evidence to equity cash still needs three transitions
Chain1: customers write calls and dealers buy them; then dealers may shortstock to hedge positive delta; then decaying/exercising calls can lead to stockrepurchases ifnetdelta falls. Callwriters earn premium, dealers earn spreads whilecarryinghedgingrisk. This is a conditionalmechanism, not observedcurrentinventory. Counterexample:customersnetlongcalls, pricechanges or rollingcontracts can reverse/offset theflow. Chain2: daily/weekly expirations expand; then hedge adjustments may distribute across moredates; then legacythird-Friday concentrationmay weaken. Cboe2025SPX0DTEshare59% substantiatesdifferentstructure but doesnotidentifycausaldecay inS&P100stocks. Chain3: publishedcalendarstrategyattractscapital; then buyingcanmoveearlier; then spreadcosts and exitcompetition can erasecashreturns. Counterexample:limits-to-arbitrage couldallowpersistence. Our gross and netmodernOEFresults areconsistentwithabsenttradablepremium, notproofwhichchaincausedit. Strongestalternative is genuineconditionaldealerflows remainprofitable despiteunconditionalfailure; that requires signedpoint-in-timeflowdata andnewuntouchedtest, notselectingfourth-Fridaywins fromcontrols. No newfund: this mechanismalreadyfitsquant andhasnoqualifiededge. Data source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=OEF,SPY,IWM&timeframe=1Day&feed=sip&adjustment=all ; https://www.sciencedirect.com/science/article/pii/S0378426613003051 .
chains3
current signed inventory observations0
2025 SPX 0DTE share pct59
gross managed mean pct-0.11
managed holdout return pct-13.3
new funds proposed0
QTR9090400 institutional calendar mechanism: consequences and counterarguments
Chain1: institutions with dated cash liabilities may sell securities before settlement deadlines; then liquidity providers absorb that supply; then prices may recover when the pressure ends. Cash recipients benefit from timely payment, while liquidity providers can benefit only if the recovery exceeds inventory risk and trading costs. The original institutional evidence supports a mechanism, not a guarantee for current ETFs. Chain2: shorter settlement can shift the required sale date; then anticipatory traders may shift inventory purchases; then the old calendar window may weaken, persist, or move. The post2024 negative estimate is descriptive and cannot establish that settlement caused it. Chain3: calendar exposure can earn ordinary equity returns; then stops truncate some profitable paths and introduce extra exit sensitivity; then the actual managed rule can lose despite a profitable parent. Here open-entry unmanaged+24.17% becomes managed-10.36% in the same frozen holdout. Strongest counterargument: the open variant still gains5.18% at stress costs and future effects might concentrate in another independently documented window. Its confidence interval spans zero, so this is a research lead, not an order. Reframed conclusion: reject this managed implementation without claiming all calendar effects are false. Fixed costs consume runway, but expected losses do not finance it. Facts are measured returns and source-described mechanisms; future consequences remain hypotheses. Sources https://www.aalto.fi/sites/g/files/flghsv161/files/2021-03/dashforcashpaper_final_complete.pdf ; https://business.purdue.edu/faculty/mcconnell/publications/Equity-Returns-at-the-Turn-of-the-Month.pdf ; https://www.sec.gov/newsroom/press-releases/2024-62 ; https://runway.adityaperswal.workers.dev/data/stock-bars .
unmanaged holdout pct24.17
managed holdout pct-10.36
unmanaged stress pct5.18
managed stress pct-24.07
allocation0
QTR9090200 consequence chains and strongest counterarguments to cash
1. AI infrastructure chain: higher memory/optics demand can lift SNDK, AXTI and LITE sales and margins; second, suppliers expand capacity and customers absorb higher component costs; third, competition, capex and repricing can reduce future scarcity margins even while trailing earnings look cheap. Samsung's strong semiconductor result alongside weaker consumer profitability illustrates differing exposures, not a causal estimate. Suppliers and issuer managers benefit from favorable demand narratives. 2. Bank chain: HSBC fee growth and NII support profits; second, dividends, buybacks and Hang Seng integration consume capital; third, credit costs/rates can bind distributions and change momentum. Shareholders benefit if capital generation persists; stale local quotes and FX remain separate implementation risks. 3. Clinical chain: ROIV efficacy or INBX response data can reprice drug expectations; second, complete safety, endpoint hierarchy and confirmatory requirements change development cost; third, financing, competition and trading gaps may overwhelm short stock drift. Sponsors benefit from funding access; repeated syndication is not independent evidence. INBX safety gap is now partly resolved by slides, not an automatic failure conclusion. 4. Strategy chain: trend persistence helps a month-long parent; second, tight range exits truncate paths and add reinvestment frictions; third, the managed holdout loses6.46% and cost stress loses13.17%. Original futures diversification and short exposure do not transfer to cash ETF sleeves. Strongest cash counterargument: recurring costs and missed rallies threaten runway. Valid conclusion is that a profitable independent rule is needed; it does not follow that the current negative rule should be funded. Counterexample to a universal stand-down: the parent is positive and some issuers show real operating improvement; these warrant evidence collection but do not establish permitted-entry payoff. Facts are reported financial data and measured simulations; all consequence mechanisms remain hypotheses. Sources analyses1386/1387/1379 and original URLs therein; https://inhibrx.com/hexagon-slides/ ; https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat ; https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results .
managed holdout pct-6.46
stress holdout pct-13.17
parent holdout pct19.22
quant cash245.69
holdings0
allocation0
QTR9090000 attack watchbook and cash: three consequence levels, no owned lots